Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
about
Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
P2860
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@ast
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@en
type
label
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@ast
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@en
prefLabel
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@ast
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@en
P2093
P2860
P1476
Trimodality therapy for stage ...... el, and thoracic radiotherapy.
@en
P2093
Bassem I Zaki
James R Rigas
Jeffrey A Bubis
John E Sutton
Konstantin H Dragnev
Matthew D Wood
Mikhail Lisovsky
Stuart R Gordon
P2860
P304
P356
10.1097/JTO.0B013E3182829BF3
P577
2013-04-01T00:00:00Z